Orthocell enters bone repair partnership
Orthocell (ASX:OCC) has teamed up with injectable bone substitute provider Bonesupport to develop products for the bone repair market.
The companies plan to develop products that combine Bonesupport’s Cerament bone substitute platform technology with Orthocell’s Celgro collagen scaffold.
Celgro will be used to help induce bone matrix formation to create a product that supports damaged bones and helps accelerate natural bone regrowth. The companies believe that Cerament’s drug eluting capabilities make it well suited to combine with collagen.
“This is an exciting step forward for both companies and further validates Celgro as a platform technology that can be used in varying surgical specialties,” Orthocell Managing Director Paul Anderson said.
“Bonesupport offers market-leading products for bone void filling and regeneration, and its agreement with Orthocell is a significant external validation of the potential of Celgro in a variety of surgical applications.”
The global bone graft and substitutes market is expected to be worth US$2.7 billion ($3.2 billion) by 2020, and the companies hope to capitalise on that market demand.
Orthocell (ASX:OCC) shares were trading 2.25% higher at $0.45 as of around 1.30 pm on Monday.
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
